Related Experiment Videos
Bleeding tendency of chronic uremia improved by vascular factor
N Di Paolo1, L Capotondo, P Rossi
1Department of Nephrology, Regional Hospital of Siena, Italy.
Nephron
|January 1, 1989
Summary
This study found that VUEFFE (VF), a new hemostatic agent, effectively reduced bleeding time in uremic patients. VF demonstrated a significant improvement in controlling bleeding without adverse effects.
Area of Science:
- Nephrology
- Hematology
- Pharmacology
Background:
- Uremic patients exhibit complex hemostatic alterations, including platelet dysfunction and prolonged bleeding.
- While dialysis improves platelet function, it can induce thrombophilia, making uremic patients a key model for hemostatic drug evaluation.
Purpose of the Study:
- To evaluate the efficacy and safety of VUEFFE (VF), a novel hemostatic agent, in hemorrhagic uremic patients.
- To assess VF's impact on bleeding time and coagulation parameters in patients undergoing dialysis or conservative management.
Main Methods:
- A randomized, placebo-controlled study involving 42 hemorrhagic uremic subjects.
- Patients received either oral VUEFFE (VF) or an oral placebo.
- Hemostasis and coagulation parameters were monitored throughout the study.
Main Results:
- 84% of patients treated with VF ceased bleeding within 15 days, compared to 25% in the placebo group.
- VUEFFE (VF) significantly reduced bleeding time without altering key clotting parameters.
- The hemostatic agent was well-tolerated, with no reported side effects.
Conclusions:
- VUEFFE (VF) is an effective and safe hemostatic agent for managing bleeding in uremic patients.
- Its ability to reduce bleeding time without affecting coagulation makes it a valuable therapeutic option.
- VF can be administered orally or parenterally, offering flexibility in patient care.